Table 1 Questions Answered by ChatGPT, Bard, and LLaMA about MEK/BRAF Inhibitors.

From: Ocular toxicities associated with MEK/BRAF inhibitors: assessing the accuracy and completeness of large language models

General Questions

1. What is a MEK/BRAF inhibitor?

2. What is the mechanism of action of a MEK/BRAF inhibitor? Be specific.

3. How common are ocular adverse effects in MEK/BRAF inhibitors?

4. What are the most common ocular adverse effects in MEK/BRAF inhibitors? Be specific.

5. What are the most severe ocular adverse effects in MEK/BRAF inhibitors?

6. What is the proposed mechanism of ocular toxicity in MEK/BRAF inhibitors?

7. How should the most common MEK/BRAF inhibitor ocular toxicity be managed?

8. How should the more advanced cases of MEK/BRAF inhibitor ocular toxicity be managed?

  1. MEK Mitogen-activated protein kinase kinase, BRAF v-Raf murine sarcoma viral oncogene homolog B.
Back to article page